A randomized, placebo-controlled trial of D-cycloserine for the enhancement of social skills training in autism spectrum disorders

Noha F Minshawi, Logan K Wink, Rebecca Shaffer, Martin H Plawecki, David J Posey, Hai Liu, Sarah Hurwitz, Christopher J McDougle, Naomi B Swiezy, Craig A Erickson, Noha F Minshawi, Logan K Wink, Rebecca Shaffer, Martin H Plawecki, David J Posey, Hai Liu, Sarah Hurwitz, Christopher J McDougle, Naomi B Swiezy, Craig A Erickson

Abstract

Background: Researchers have demonstrated that d-cycloserine (DCS) can enhance the effects of behavioral interventions in adults with anxiety and enhances prosocial behavior in animal models of autism spectrum disorders (ASD). This study extended upon this background by combining DCS with behavioral social skills therapy in youth with ASD to assess its impact on the core social deficits of ASD. We hypothesized that DCS used in combination with social skills training would enhance the acquisition of social skills in children with ASD.

Methods: A 10-week, double-blind, placebo-controlled trial of DCS (50 mg) given 30 min prior to weekly group social skills training was conducted at two sites. Children with ASD were randomized to receive 10 weeks (10 doses) of DCS or placebo in a 1:1 ratio.

Results: No statistically significant difference attributable to drug treatment was observed in the change scores for the primary outcome measure, the Social Responsiveness Scale (SRS), total score (p = 0.45), or on secondary outcome measures.

Conclusions: The results of this trial demonstrated no drug-related short-term improvement on the primary outcome measure, or any of the secondary outcome measures. However, an overall significant improvement in SRS total raw score was observed from baseline to end of treatment for the entire group of children with ASD. This suggests a need to further study the efficacy of the social skills training protocol. Limitations to the current study and areas for future research are discussed.

Trial registration: ClinicalTrials.govNCT01086475.

Keywords: Autism spectrum disorders; Social deficits; Social skills training; d-cycloserine.

Figures

Fig. 1
Fig. 1
Social responsiveness scale raw score across time points

References

    1. Kanner L. Autistic disturbances of affective contact. Nervous Child. 1943;2:217–250.
    1. CDC . Prevalence of autism spectrum disorder among children aged 8 years—autism and developmental disabilities monitoring network, 11 sites, United States. 2010.
    1. Wink LK, Erickson CA, McDougle CJ. Pharmacologic treatment of behavioral symptoms associated with autism and other pervasive developmental disorders. Curr Treat Options Neurol. 2010;12(6):529–538. doi: 10.1007/s11940-010-0091-8.
    1. Blankenship K, Stigler KA, Erickson CA, Posey DJ, McDougle CJ. Psychopharmacoloigcal treatment of autism. In: Amaral D, Dawson G, Geschwind D, editors. Autism spectrum disorders. New York: Oxford University Press; 2011. pp. 1194–1212.
    1. Posey DJ, Erickson CA, McDougle CJ. Developing drugs for core social and communication impairment in autism. Child Adolesc Psychiatr Clin N Am. 2008;17(4):787–801. doi: 10.1016/j.chc.2008.06.010.
    1. Magiati I, Tay XW, Howlin P. Cognitive, language, social and behavioural outcomes in adults with autism spectrum disorders: a systematic review of longitudinal follow-up studies in adulthood. Clin Psychol Rev. 2014;34(1):73–86. doi: 10.1016/j.cpr.2013.11.002.
    1. McDougle CJ, Erickson CA, Stigler KA, Posey DJ. Neurochemistry in the pathophysiology of autism. J Clin Psychiatry. 2005;66(Suppl 10):9–18.
    1. Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA, et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry. 1999;56(1):21–27. doi: 10.1001/archpsyc.56.1.21.
    1. van Berckel BN, Evenblij CN, van Loon BJ, Maas MF, van der Geld MA, Wynne HJ, et al. D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study. Neuropsychopharmacology. 1999;21(2):203–210. doi: 10.1016/S0893-133X(99)00014-7.
    1. Goff DC, Cather C, Gottlieb JD, Evins AE, Walsh J, Raeke L, et al. Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study. Schizophr Res. 2008;106(2–3):320–327. doi: 10.1016/j.schres.2008.08.012.
    1. Goff DC, Herz L, Posever T, Shih V, Tsai G, Henderson DC, et al. A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology. 2005;179(1):144–150. doi: 10.1007/s00213-004-2032-2.
    1. Duncan EJ, Szilagyi S, Schwartz MP, Bugarski-Kirola D, Kunzova A, Negi S, et al. Effects of D-cycloserine on negative symptoms in schizophrenia. Schizophr Res. 2004;71(2–3):239–248. doi: 10.1016/j.schres.2004.03.013.
    1. Posey DJ, Kem DL, Swiezy NB, Sweeten TL, Wiegand RE, McDougle CJ. A pilot study of D-cycloserine in subjects with autistic disorder. Am J Psychiatry. 2004;161(11):2115–2117. doi: 10.1176/appi.ajp.161.11.2115.
    1. Posey DJ, Stigler KA, Erickson CA, Azzouz F, Wilkerson J, Mullett J, et al., editors. A double-blind, placebo-controlled study of D-cycloserine in children with autistic disorder. Boca Raton: American College of Neuropsychopharmacology; 2007.
    1. Swanson CJ, Bures M, Johnson MP, Linden A-M, Monn JA, Schoepp DD. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov. 2005;4(2):131–144. doi: 10.1038/nrd1630.
    1. Cortese BM, Phan KL. The role of glutamate in anxiety and related disorders. CNS Spectrums. 2005;10(10):820–30.
    1. Norberg MM, Krystal JH, Tolin DF. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry. 2008;63(12):1118–26. doi: 10.1016/j.biopsych.2008.01.012.
    1. Rodrigues H, Figueira I, Lopes A, Goncalves R, Mendlowicz MV, Coutinho ES, et al. Does D-cycloserine enhance exposure therapy for anxiety disorders in humans? A meta-analysis. PLoS One. 2014;9(7) doi: 10.1371/journal.pone.0093519.
    1. Modi ME, Young LJ. D-cycloserine facilitates socially reinforced learning in an animal model relevant to autism spectrum disorders. Biol Psychiatry. 2011;70(3):298–304. doi: 10.1016/j.biopsych.2011.01.026.
    1. Foxx RM. Applied behavior analysis treatment of autism: the state of the art. Child Adolesc Psychiatr Clin N Am. 2008;17(4):821–34. doi: 10.1016/j.chc.2008.06.007.
    1. Scattone D, Tingstrom DH, Wilczynski SM. Increasing appropriate social interactions of children with autism spectrum disorders using social stories. Focus Autism Other Developmental Disabilities. 2006;21(4):211–22. doi: 10.1177/10883576060210040201.
    1. Schneider N, Goldstein H. Using social stories and visual schedules to improve socially appropriate behaviors in children with autism. J Posit Behav Interv. 2010;12(3):149–60. doi: 10.1177/1098300709334198.
    1. Koegel L, Vernon T, Koegel RL, Koegel B, Paullin AW. Improving socialization between children with autism spectrum disorder and their peers in inclusive settings. J Posit Behav Interv. 2012;14(4):220–7. doi: 10.1177/1098300712437042.
    1. Reichow B, Volkmar FR. Social skills interventions for individuals with autism: evaluation for evidence-based practices within a best evidence synthesis framework. J Autism Dev Disord. 2010;40:149–66. doi: 10.1007/s10803-009-0842-0.
    1. Stone W, Ruble L, Coonrod E, Hepburn S, Pennington M. TRIAD social skills assessment manual. Nashville, TN: Treatment and Research Institute for Autism Spectrum Disorders; 2003.
    1. Pozdol SL SN, Stuart ML, Beach EB, Beach EB, editors. Social skills training in children with ASD: a comparison of weekly groups and summer camp formats. Annual convention of the association for behavior analysis. Social skills training in children with ASD: a comparison of weekly groups and summer camp formats. Annual convention of the Association for Behavior Analysis. San Diego: Association for Behavior Analysis; 2007.
    1. Lord C, Rutter M, Goode S, Heemsbergen J, Jordan H, Mawhood L, et al. Autism diagnostic observation schedule: a standardized observation of communicative and social behavior. J Autism Dev Disord. 1989;19(2):185–212. doi: 10.1007/BF02211841.
    1. Gotham K, Risi S, Pickles A, Lord C. The autism diagnostic observation schedule: revised algorithms for improved diagnostic validity. J Autism Dev Disord. 2007;37(4):613–27. doi: 10.1007/s10803-006-0280-1.
    1. Lord C, Pickles A, McLennan J, Rutter M, Bregman J, Folstein S, et al. Diagnosing autism: analyses of data from the autism diagnostic interview. J Autism Dev Disord. 1997;27(5):501–17. doi: 10.1023/A:1025873925661.
    1. Association AP. Diagnostic and statistical manual of mental disorders, fourth edition, text revision. Washington, DC: American Psychiatric Association; 2000.
    1. Roid GH. Stanford-Binet intelligence scales for early childhood. Fifth 2005.
    1. Sparrow SS, Cicchetti DV, Balla DA. Vineland adaptive behavior scales. Second 2008.
    1. Constantino JN, Gruber CP. Social responsiveness scale. 2005.
    1. Sprafkin J, Gadow KD. Child symptom inventory 4. 2002.
    1. Marrus N, Underwood-Riordan H, Randall F, Zhang Y, Constantino JN. Lack of effect of risperidone on core autistic symptoms: data from a longitudinal study. J Autism Dev Disord. 2014;24(9):513–8.
    1. Lyall K, Constantino JN, Weisskopf MG, Roberts AL, Ascherio A, Santangelo SL. Parental social responsiveness and risk of autism spectrum disorder in offspring. JAMA Psychiatry. 2014;71(8):936–42. doi: 10.1001/jamapsychiatry.2014.476.
    1. Erickson CA, Veenstra-Vanderweele JM, Melmed RD, McCracken JT, Ginsberg LD, Sikich L, et al. STX209 (arbaclofen) for autism spectrum disorders: an 8-week open-label study. J Autism Dev Disord. 2014;44(4):958–64. doi: 10.1007/s10803-013-1963-z.
    1. Hardan AY, Fung LK, Libove RA, Obukhanych TV, Nair S, Herzenberg LA, et al. A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biol Psychiatry. 2012;71(11):956–61. doi: 10.1016/j.biopsych.2012.01.014.
    1. Aman MG, Singh NN. Aberrant behavior checklist. 1986.
    1. Fisch GS. Adaptive behavior in children with autism. J Autism Dev Disord. 2001;31(2):249. doi: 10.1023/A:1010719720000.
    1. Freeman BJ, Del’Homme M, Guthrie D, Zhang F. Vineland adaptive behavior scale scores as a function of age and initial IQ in 210 autistic children. J Autism Dev Disord. 1999;29(5):379–84. doi: 10.1023/A:1023078827457.
    1. McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347(5):314–21. doi: 10.1056/NEJMoa013171.
    1. Murray DS, Ruble LA, Willis H, Molloy CA. Parent and teacher report of social skills in children with autism spectrum disorders. Lang Speech Hear Serv Sch. 2009;40(2):109–15. doi: 10.1044/0161-1461(2008/07-0089).
    1. Ruble L, Willis H, Crabtree VM. Social skills group therapy for autism spectrum disorders. Clinical Case Studies. 2008;7(4):287–300. doi: 10.1177/1534650107309450.
    1. Guastella AJ, Gray KM, Rinehart NJ, Alvares GA, Tonge BJ, Hickie IB, et al. The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: a randomized controlled trial. J Child Psychol Psychiatry. 2015;56(4):444–52. doi: 10.1111/jcpp.12305.
    1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5™ (5th ed.). Arlington, VA, US: American Psychiatric Publishing, Inc.; 2013.
    1. Ressler KJ, Rothbaum BO, Tannenbaum L, Anderson P, Graap K, Zimand E, et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry. 2004;61(11):1136–44. doi: 10.1001/archpsyc.61.11.1136.
    1. Hofmann SG, Meuret AE, Smits JA, Simon NM, Pollack MH, Eisenmenger K, et al. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry. 2006;63(3):298–304. doi: 10.1001/archpsyc.63.3.298.
    1. Gresham FM, Elliot SN. Social Skills Improvement system-rating scales. Minneapolis: Pearson Assessments; 2008.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren